-
Sep 30, 2024 | 
ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |George Bertsias |Dimitrios T. Boumpas
Response to: Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al Free Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
May 22, 2024 | 
ard.bmj.com | Myrto Kostopoulou |Chetan Mukhtyar |George Bertsias |Dimitrios T. Boumpas
DiscussionFor the recent update of the EULAR recommendations for the management of SLE, we performed five different SLRs based on respective PICOs, to cover the most important aspects in the treatment of this challenging disease. HCQ is the backbone treatment for all patients with SLE, while GC are still used in the majority of patients. The current SLR confirmed the beneficial effects of HCQ in lupus, ranging from prevention of infections or thrombosis to improved survival.
-
Apr 5, 2024 | 
ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |George Bertsias |Dimitrios T. Boumpas
Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
-
Jan 1, 2024 | 
ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |Jeanette H. Andersen |Martin Aringer
Handling editor David S PisetskyTwitter @cmukhtyar, @edvital, @chriswincup, @george_bertsias, @noneContributors AF and MK reviewed the literature and AF drafted the manuscript. GB and CBM supervised the methodology. All authors edited the manuscript. DTB supervised the project. Funding European League against Rheumatism (project number QoC015).
-
Jan 1, 2024 | 
ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |Jeanette H. Andersen |Martin Aringer
Dear Editor,The 2023 update of the EULAR recommendations for the management of systemic lupus erythematosus (SLE) recommend hydroxychloroquine (HCQ) for all patients with SLE at a target dose of 5 mg/kg real body weight (RBW)/day but also suggest individualizing the regimen in accordance with the risk of flares or retinal toxicity.
-
Oct 12, 2023 | 
ard.bmj.com | Antonis Fanouriakis |Myrto Kostopoulou |Jeanette H. Andersen |Martin Aringer
DiscussionFor these recommendations, we assembled a Task Force of world-leading experts in the field of SLE from four continents, to assure the widest possible representation and broad expertise. This is particularly important, because SLE across the world is very different in terms of presentation and severity.
-
Oct 12, 2023 | 
dx.doi.org | Antonis Fanouriakis |Myrto Kostopoulou |Jeanette Hammer Andersen |Martin Aringer
DiscussionFor these recommendations, we assembled a Task Force of world-leading experts in the field of SLE from four continents, to assure the widest possible representation and broad expertise. This is particularly important, because SLE across the world is very different in terms of presentation and severity.
-
May 11, 2023 | 
ard.bmj.com | Myrto Kostopoulou |Antonis Fanouriakis |George Bertsias |Dimitrios T. Boumpas
http://orcid.org/0000-0002-8832-7475Myrto Kostopoulou1, http://orcid.org/0000-0003-2696-031XAntonis Fanouriakis1,2, George Bertsias3,4, http://orcid.org/0000-0002-9812-4671Dimitrios T Boumpas1,5 1 Rheumatology and Clinical Immunology, National and Kapodistrian University, Athens, Greece 2 First Department of Propaedeutic Internal Medicine, National and Kapodistrian University, Athens, Greece 3 Rheumatology, University of Crete School of Medicine, Iraklio, Greece 4 Laboratory of...
-
Apr 24, 2023 | 
ard.bmj.com | Myrto Kostopoulou |Antonis Fanouriakis |George Bertsias |Dimitrios T. Boumpas
Part I: pathogenesis and novel molecular targets: new and old playersWhy do some patients with SLE develop LN? The interaction of genes and environmentLN has a high genetic loadPatients with SLE with severe disease—including nephritis—have a high genetic risk score—calculated based on 57 SLE risk loci—and are more likely to develop lupus earlier, accrue damage and have decreased survival.
-
Apr 24, 2023 | 
ard.bmj.com | Myrto Kostopoulou |Antonis Fanouriakis |George Bertsias |Dimitrios T. Boumpas
Part I: pathogenesis and novel molecular targets: new and old playersWhy do some patients with SLE develop LN? The interaction of genes and environmentLN has a high genetic loadPatients with SLE with severe disease—including nephritis—have a high genetic risk score—calculated based on 57 SLE risk loci—and are more likely to develop lupus earlier, accrue damage and have decreased survival.
